Imetelstat
Who should not take RYTELO?
Before taking RYTELO, tell your healthcare provider about all your medical conditions, including if you:
Myelodysplastic Syndromes (MDS)
Understanding Brain Fog, Chemo Brain, with Dr. Jorg Dietrich
Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
Presenter(s)
Jorg Dietrich, MD, PhD
In this webinar, Dr. Jorg Dietrich will discusses the diagnosis of brain fog/chemo brain and how patients can manage this symptom of disease and its treatments.
Advances in Transplant and GVHD with Dr. Corey Cutler
Topic(s)
Bone Marrow Transplant
Presenter(s)
Corey Cutler, MD, MPH, FRCPC
In this webinar, Dr. Corey Cutler discusses advances in transplant and treating GVHD, or Graft Versus Host Disease.
IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML
Original Publication Date
Article Source
External Web Content
Immunohistochemistry (IHC) could represent a biomarker for the early detection of TP53 mutations and for the prediction of a TP53 allelic state in patients with myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), according to data from an observational trial…
A clinical guide to TP53 mutations in myeloid neoplasms
Original Publication Date
Article Source
External Web Content
TP53 mutations are found in 10-15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multi-hit TP53 mutant myeloid neoplasms having a very poor prognosis…
Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome
Original Publication Date
Article Source
External Web Content
Key Points NK cells phenotyping reveals impaired cytotoxicity, chronic activation and exhaustion in VEXAS syndrome. Decreased circulating NK cells were independently associated with an increased risk of severe infections in VEXAS syndrome. VEXAS (vacuoles, E1 enzyme, X-linked…
Clinical Study on Targeted Drug Expands Treatment Options for Myelodysplastic Syndrome
Original Publication Date
Article Source
External Web Content
Their research led to the 2022 approval of olutasidenib for certain patients with IDH1-mutant AML, which occurs in about 10% of AML. After that success, Dr. Watts and his team began to focus closely on testing the drug in MDS, a related condition that often progresses to AML. IDH…
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
Original Publication Date
Article Source
External Web Content
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This combination may be an opportune bridge to transplantation, according to David A. Sallman, MD, of the…
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
Original Publication Date
Article Source
External Web Content
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This combination may be an opportune bridge to transplantation, according to David A. Sallman, MD, of the…
SRSF2-mutated MDS: bortezomib STAT?
Original Publication Date
Article Source
External Web Content
In this issue of Blood, Takashima et al show that reduced STAT1 abundance in SRSF2-mutant myelodysplastic syndrome (MDS) cells confers protection against interferon (IFN)-driven cell suppression relative to normal wild-type (WT) cells.1 Importantly, the authors demonstrate that…